Developing therapies for cancers harbouring KRAS mutations has proven difficult but PROTACs, acting via targeted protein degradation, may help combat previously undruggable proteins 

A study associates reductions in ctDNA with major pathologic response following neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC, but clinical application is still some way off

Sub-group analyses of CheckMate 227 part 1 provide reassurance but no definite guidance regarding standard treatment for different patient sub-groups 

Results from an exploratory analysis of the IMpower010 trial confirm that there is a correlation between tumour-cell PD-L1 expression and disease-free survival 

Along with treatments with immune checkpoint inhibitors and cellular therapies, other immunotherapies are currently under investigation

Immunotherapy plus chemotherapy as first-line treatment choice for advanced disease without oncogene mutations, irrespective of ethnicity and PD-L1 status 

In the first interim analysis of the ORIENT-31 trial, progression-free survival was slightly improved in patients who progressed after EGFR TKI, but mature results are needed to confirm whether combination therapy represents a new therapeutic option in this setting

However, regulatory and financial issues will shape when and where this happens  

Sequencing data suggest that non-G12C KRAS mutations could mediate intrinsic resistance to treatments in non-small-cell lung cancer, but functional confirmation is required 

AKT and EZH2 are identified as potential therapeutic targets to limit acquired resistance to osimertinib in patients with EGFR-mutated tumours of the lung